Inclusion Criteria:

- Pathologic documentation of adenocarcinoma of the colon with or without penetration
of the serosa with no lymph node metastases (Stage II pT3N0 or pT4bNO lesions,
excluding pT4aN0; Modified Astler-Coller Stage B2); there can be no distant
metastases or penetration of adjacent organs or structures; proximal, distal, and
radial margins must be free of tumor Important note: A tumor nodule > 3 mm in
diameter in the perirectal or pericolonic adipose tissue without histologic evidence
of residual node in the nodule is classified as regional/pericolonic node metastasis;
however, a tumor nodule =< 3 mm in diameter is classified in the T category as
discontinuous extension (i.e., pT3); multiple metastatic foci seen microscopically
only in the pericolonic fat should be considered as metastasis in a single lymph node
for classification; although six or more nodes evaluated from the specimen is
optimal, a minimum of three nodes (periodic or mesenteric) for evaluation is required
for inclusion in the study

- Complete, en bloc resection of all the primary tumor, performed as an open procedure,
and not laparoscopically or laparoscopically assisted

- No evidence of perforation or clinical obstruction of the bowel

- The gross distal margin of the primary tumor must lie above the peritoneal reflection
(i.e., it must be a colon, not a rectal cancer)

- No previous radiation or chemotherapy for this malignancy

- CALGB Performance status 0-1

- No concurrent treatment with systemic steroids is allowed; patients receiving
replacement steroids for adrenal insufficiency are eligible; patients receiving
inhaled steroids in daily doses of 500mg or less and patients being treated with
topical steroids are eligible

- No prior exposure to murine antibodies (e.g., diagnostic tests like the "oncoscint
scan")

- No uncontrolled or severe cardiovascular disease

- No history of pancreatitis

- Non-pregnant and non-lactating; patients of child-bearing potential should agree to
use an effective method of birth control

- No previous or concurrent malignancy is allowed, except inactive non-melanoma skin
cancer, in situ carcinoma of the cervix, or other cancer if the patient has been
disease-free for >= 5 years; patients with more than one synchronous primary colon
tumor are eligible; for the purpose of this protocol, staging classification will be
based on the stage of the more advanced primary tumor

- Granulocytes > 1,800/μl

- Platelet count > 100,000/μl

- BUN < 1.5 x normal

- Creatinine < 1.5 x normal

- Bilirubin < 1.5 x normal